Clinical data | |
---|---|
Trade names | Picato |
Other names | PEP005, ingenol-3-angelate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613008 |
License data | |
Pregnancy category |
|
Routes of administration | Topical (gel) |
Drug class | Macrocyclic diterpene ester[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Below detection level |
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H34O6 |
Molar mass | 430.541 g·mol−1 |
3D model (JSmol) | |
| |
|
Ingenol mebutate, sold under the brand name Picato, is a medication used to treat actinic keratosis.[1] It is applied to the skin once per day for 2 to 3 days.[1] It appears to work the same as fluorouracil or imiquimod.[1]
Common side effects include redness, skin peeling, blistering, and itchiness.[1] Other side effects may include skin cancer in an extra 4% of people, allergic reactions, and shingles.[2][1] Safety in pregnancy is unclear.[1] It is a macrocyclic diterpene ester.[1]
Ingenol mebutate was approved for medical use in the United States in 2012.[1] While it was approved in Europe in 2012, it was subsequently withdrawn due to concerns regarding side effects.[3][2] In the United States three doses costs about 1,100 USD as of 2021.[4] It from the sap of the milkweed plant.[1]
References
edit- ^ a b c d e f g h i j k l "Ingenol Mebutate Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 26 November 2021.
- ^ a b "Risks of Picato for actinic keratosis outweigh benefits". Archived from the original on 5 January 2021. Retrieved 26 November 2021.
- ^ "Picato". Archived from the original on 28 August 2021. Retrieved 26 November 2021.
- ^ "Picato Prices and Picato Coupons - GoodRx". GoodRx. Archived from the original on 1 October 2016. Retrieved 26 November 2021.